☆ 4.7 Letter

Emergence of SARS-COV-2 Spike Protein Escape Mutation Q493R after Treatment for COVID-19

EMERGING INFECTIOUS DISEASES (2021)

Related references

Note: Only part of the references are listed.
Article Health Care Sciences & Services

Emergence of the E484K mutation in SARS-COV-2-infected immunocompromised patients treated with bamlanivimab in Germany

Bjoern Jensen et al.

Summary: The study indicates that treatment of SARS-CoV-2 with bamlanivimab in immunocompromised patients may result in the rapid development of immune escape variants, which could have significant implications for the effectiveness of vaccination and antibody-based therapies.

LANCET REGIONAL HEALTH-EUROPE (2021)

Add to Collection
Letter Immunology

Imported SARS-CoV-2 Variant P.1 in Traveler Returning from Brazil to Italy

Fabrizio Maggi et al.

Summary: This case is an imported one where an asymptomatic traveler arrived in Italy and tested positive for the SARS-CoV-2 variant P.1 after traveling indirectly from Brazil, highlighting the risk of introducing SARS-CoV-2 variants through indirect flights and the importance of continued surveillance for SARS-CoV-2.

EMERGING INFECTIOUS DISEASES (2021)

Add to Collection
Article Cell Biology

Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016

Tyler N. Starr et al.

Summary: The study mapped mutations to the SARS-CoV-2 spike receptor-binding domain that escape binding by certain monoclonal antibodies. These mutations are concentrated in specific lineages of SARS-CoV-2. The authors suggest diversifying the epitopes targeted by antibodies and antibody cocktails to make them more resilient to SARS-CoV-2 antigenic evolution.

CELL REPORTS MEDICINE (2021)

Add to Collection
Letter Medicine, General & Internal

Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host

Bina Choi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.